ATE386938T1 - Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen - Google Patents

Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen

Info

Publication number
ATE386938T1
ATE386938T1 AT99950002T AT99950002T ATE386938T1 AT E386938 T1 ATE386938 T1 AT E386938T1 AT 99950002 T AT99950002 T AT 99950002T AT 99950002 T AT99950002 T AT 99950002T AT E386938 T1 ATE386938 T1 AT E386938T1
Authority
AT
Austria
Prior art keywords
cancer
ykl
marker
indicator
predicting cancer
Prior art date
Application number
AT99950002T
Other languages
English (en)
Inventor
Paul Price
Julia Johansen
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE386938T1 publication Critical patent/ATE386938T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT99950002T 1998-10-01 1999-09-29 Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen ATE386938T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/164,862 US7229770B1 (en) 1998-10-01 1998-10-01 YKL-40 as a marker and prognostic indicator for cancers

Publications (1)

Publication Number Publication Date
ATE386938T1 true ATE386938T1 (de) 2008-03-15

Family

ID=22596399

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99950002T ATE386938T1 (de) 1998-10-01 1999-09-29 Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen

Country Status (8)

Country Link
US (2) US7229770B1 (de)
EP (2) EP1804062A3 (de)
JP (1) JP2002525632A (de)
AT (1) ATE386938T1 (de)
AU (1) AU6275799A (de)
CA (1) CA2343972A1 (de)
DE (1) DE69938187D1 (de)
WO (1) WO2000019206A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034469A1 (en) * 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
JP2006508014A (ja) * 2001-07-24 2006-03-09 イエール・ユニバーシテイ キチナーゼおよびキチナーゼ様分子、ならびに炎症性疾患に関する方法、組成物およびキット
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
WO2005039487A2 (en) * 2003-09-10 2005-05-06 Sloan-Kettering Institute For Cancer Research Method for early detection of ovarian cancer
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
ES2534752T3 (es) * 2004-12-07 2015-04-27 Toray Industries, Inc. Nuevo péptido antigénico contra el cáncer y utilización del mismo
PL1856153T3 (pl) 2005-02-28 2011-06-30 Bio Y As Przeciwciała monoklonalne YKL-40
US20100196509A1 (en) * 2005-02-28 2010-08-05 Jonathan Braun Methods for Diagnosis and Treatment of Endometrial Cancer
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
US8648052B2 (en) * 2005-04-15 2014-02-11 The Regents Of The University Of California Prevention of chlamydia infection using SIRNA
WO2006113526A2 (en) 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
US8409411B2 (en) * 2005-12-02 2013-04-02 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Portland State University Nano-porous membrane based sensors
WO2007081385A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
CA2644586A1 (en) * 2006-03-03 2008-04-17 Veridex Llc Molecular assay to predict recurrence of duke's b colon cancer
US20110143380A1 (en) * 2006-03-14 2011-06-16 The Washington University Alzheimer's disease biomarkers and methods of use
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530167A1 (de) 2006-05-11 2012-12-05 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
EP2077912B1 (de) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
FR2908654B1 (fr) * 2006-11-20 2014-04-04 Oreal Utilisation cosmetique de proteines de type chitinase
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2011063161A2 (en) 2009-11-20 2011-05-26 The Regents Of The University Of California Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
JP5346957B2 (ja) * 2008-01-23 2013-11-20 ヘルレフ ホスピタル 不特定疾患の汎用マーカーとしてのｙｋｌ−４０
WO2009092382A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet, Region Hovedstaden Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP4047367A1 (de) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
WO2010028658A1 (en) * 2008-09-15 2010-03-18 Herlev Hospital, Region Hovedstaden Ykl-40 as a marker for gastrointestinal cancers
WO2010028656A1 (en) * 2008-09-15 2010-03-18 Herlev Hospital, Region Hovedstaden Methods for classifying the severity of diseases or disorders
EP2344886A1 (de) * 2008-09-15 2011-07-20 Herlev Hospital Ykl-40 als marker zur auswahl der behandlung und überwachung einer krankheit
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
RU2423707C2 (ru) * 2009-06-30 2011-07-10 Федеральное государственное учреждение науки Казанский научно-исследовательский институт эпидемиологии и микробиологии Роспотребнадзора Способ определения хитиназо-подобного белка ykl-40 в биоптатах и экскретах человека
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
US8198035B2 (en) 2009-11-25 2012-06-12 Siemens Healthcare Diagnostics Inc. Galactose-α-1,3-galactose-macromolecule conjugates and methods employing same
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
EP4484577A3 (de) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digitale analytanalyse
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
EP3412778A1 (de) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
WO2012112804A1 (en) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
EP2694974B1 (de) 2011-04-04 2015-10-21 Universiteit Gent Marker für akute nierenläsion
US20130035290A1 (en) * 2011-05-17 2013-02-07 Yale University Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3216872B1 (de) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzymquantifizierung
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US9575073B2 (en) * 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP2844768B1 (de) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digitale analyse von analyten
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
RU2623869C1 (ru) * 2016-07-29 2017-06-29 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский государственный университет" (ТГУ, НИ ТГУ) Способ прогнозирования безрецидивной выживаемости у больных раком молочной железы
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
WO2020163581A1 (en) * 2019-02-06 2020-08-13 Berg Llc Markers for the diagnosis of biochemical recurrence in prostate cancer
CN114096850A (zh) * 2019-07-08 2022-02-25 株式会社明治 预测癌症患者的预后的方法、预测抗癌疗法的有效性的方法和选择适合癌症患者的疗法的方法
KR102142499B1 (ko) 2019-09-11 2020-08-10 재단법인 오송첨단의료산업진흥재단 Ykl-40 표적 인간 단일클론항체
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN114569725B (zh) * 2022-03-29 2023-05-12 潍坊医学院 Ykl-40在黑色素瘤治疗中的应用
KR102820652B1 (ko) 2022-05-10 2025-06-16 재단법인 오송첨단의료산업진흥재단 항-키티나제-3-유사 단백질 1 항체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628027A (en) 1982-05-19 1986-12-09 Molecular Engineering Associates, Ltd. Vitro diagnostic methods using monoclonal antibodies against connective tissue proteins
US4828981A (en) * 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
JPS6323898A (ja) 1986-07-16 1988-02-01 Dainippon Pharmaceut Co Ltd 新規ポリペプチド及びそれをコ−ドするｄｎａ並びにそれらの製法
US5427954A (en) 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
CA2164498C (en) 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
US5773259A (en) 1996-03-20 1998-06-30 Smithkline Beecham Corporation Tissue remodeling proteins
EP0805206A3 (de) 1996-05-03 1999-09-15 Smithkline Beecham Corporation Menschliches Glycoprotein aus Knorpel
US5811535A (en) * 1996-08-09 1998-09-22 Smithkline Beecham Corporation Human cartilege gp39-like gene
AU6693996A (en) 1996-08-09 1998-03-06 Human Genome Sciences, Inc. Human chitinase alpha and chitinase alpha-2
US5726061A (en) * 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
PL1856153T3 (pl) 2005-02-28 2011-06-30 Bio Y As Przeciwciała monoklonalne YKL-40

Also Published As

Publication number Publication date
WO2000019206A1 (en) 2000-04-06
EP1804062A2 (de) 2007-07-04
CA2343972A1 (en) 2000-04-06
AU6275799A (en) 2000-04-17
US7670599B2 (en) 2010-03-02
EP1112497A1 (de) 2001-07-04
WO2000019206A9 (en) 2000-09-08
EP1112497B1 (de) 2008-02-20
US7229770B1 (en) 2007-06-12
US20050226884A1 (en) 2005-10-13
DE69938187D1 (de) 2008-04-03
EP1804062A3 (de) 2007-07-11
JP2002525632A (ja) 2002-08-13

Similar Documents

Publication Publication Date Title
ATE386938T1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
DK1734368T3 (da) Annexin-autoantistoffer anvendt som markörer for lungecancer
ATE337011T1 (de) Modifizierte psma-liganden und deren verwendung
ATE352641T1 (de) Zirkulierendes epstein-barr virus dna im serum der patienten mit gastrischem krebs
ATE337413T1 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
ATE331811T1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
ATE534905T1 (de) Cop1-moleküle und verwendungen davon
ATE424560T1 (de) Marker für neuromyelitis optica
DE69929785D1 (de) Verfahren zur Diagnose, Erkennung, und Einstufung von Dickdarmkrebs
ATE535612T1 (de) Toxizitätsscreeningverfahren
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE522620T1 (de) Nachweis von micrometastasierung von melanomen und brustkrebs an in paraffin eingegbetteten, von tumoren abführenden lymphknoten mittels quantitativer multimaker rt-pcr
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2002064015A3 (en) Pin1 as a marker for prostate cancer
BR0314155A (pt) Métodos para diagnosticar câncer cervical
DK2199801T3 (da) Biomarkører til tidlig påvisning af ovariecancer
ATE274188T1 (de) Verfahren zur bestimmung eines analyten und kit dafür
ATE377192T1 (de) Diagnostisches verfahren für eierstock- und endometriumtumore basierend auf dem nachweis des l1-adhäsionsmoleküls
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
EP1281083A4 (de) Verfahren zur erkennung von entzündungen und entzündungsbedingungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties